PDT Partners LLC Has $1.83 Million Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

PDT Partners LLC decreased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 27.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,263 shares of the medical research company's stock after selling 3,500 shares during the period. PDT Partners LLC's holdings in Charles River Laboratories International were worth $1,825,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Boston Trust Walden Corp increased its holdings in shares of Charles River Laboratories International by 2.8% during the second quarter. Boston Trust Walden Corp now owns 200,314 shares of the medical research company's stock worth $41,381,000 after buying an additional 5,375 shares in the last quarter. Tidal Investments LLC increased its holdings in shares of Charles River Laboratories International by 99.8% in the first quarter. Tidal Investments LLC now owns 5,297 shares of the medical research company's stock valued at $1,435,000 after purchasing an additional 2,646 shares in the last quarter. Quest Partners LLC increased its holdings in shares of Charles River Laboratories International by 135,175.0% in the second quarter. Quest Partners LLC now owns 5,411 shares of the medical research company's stock valued at $1,118,000 after purchasing an additional 5,407 shares in the last quarter. New England Research & Management Inc. acquired a new stake in shares of Charles River Laboratories International in the second quarter valued at approximately $506,000. Finally, Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Charles River Laboratories International by 3.4% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 111,995 shares of the medical research company's stock valued at $22,060,000 after purchasing an additional 3,714 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on CRL. The Goldman Sachs Group dropped their target price on shares of Charles River Laboratories International from $290.00 to $250.00 and set a "buy" rating for the company in a research report on Thursday, August 8th. Redburn Atlantic began coverage on shares of Charles River Laboratories International in a research report on Monday, October 14th. They set a "sell" rating and a $151.00 target price for the company. Robert W. Baird dropped their target price on shares of Charles River Laboratories International from $191.00 to $190.00 and set a "neutral" rating for the company in a research report on Friday, September 20th. StockNews.com cut shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. cut shares of Charles River Laboratories International from an "overweight" rating to a "neutral" rating and dropped their target price for the company from $270.00 to $205.00 in a research report on Thursday, August 8th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Charles River Laboratories International currently has a consensus rating of "Hold" and an average price target of $214.38.

Charles River Laboratories International Stock Down 0.3 %

Shares of Charles River Laboratories International stock traded down $0.53 during trading hours on Friday, reaching $199.06. 287,759 shares of the company's stock were exchanged, compared to its average volume of 780,522. The company has a 50 day moving average of $194.32 and a two-hundred day moving average of $204.75. Charles River Laboratories International, Inc. has a fifty-two week low of $176.48 and a fifty-two week high of $275.00. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The stock has a market cap of $10.18 billion, a P/E ratio of 24.91, a P/E/G ratio of 5.13 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping analysts' consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. During the same period in the prior year, the business posted $2.72 EPS. The company's quarterly revenue was down 1.6% on a year-over-year basis. On average, sell-side analysts forecast that Charles River Laboratories International, Inc. will post 10.19 EPS for the current fiscal year.

Charles River Laboratories International declared that its board has authorized a stock buyback plan on Wednesday, August 7th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 9.6% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's leadership believes its shares are undervalued.

Insider Activity

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares of the company's stock, valued at $2,676,862.32. This represents a 34.83 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).